Tenaya Therapeutics (NASDAQ:TNYA) Major Shareholder Group Gp Lp Column III Sells 343,717 Shares

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) major shareholder Group Gp Lp Column III sold 343,717 shares of the business’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $0.82, for a total value of $281,847.94. Following the sale, the insider owned 4,253,298 shares in the company, valued at approximately $3,487,704.36. The trade was a 7.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Wednesday, February 11th, Group Gp Lp Column III sold 4,056,573 shares of Tenaya Therapeutics stock. The shares were sold at an average price of $0.68, for a total transaction of $2,758,469.64.

Tenaya Therapeutics Price Performance

Tenaya Therapeutics stock traded up $0.00 during midday trading on Thursday, reaching $0.68. The stock had a trading volume of 4,480,550 shares, compared to its average volume of 3,880,488. The firm’s fifty day simple moving average is $0.83 and its two-hundred day simple moving average is $1.15. Tenaya Therapeutics, Inc. has a twelve month low of $0.36 and a twelve month high of $2.35. The firm has a market cap of $113.83 million, a price-to-earnings ratio of -0.88 and a beta of 3.18.

Tenaya Therapeutics (NASDAQ:TNYA) last released its earnings results on Monday, November 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. As a group, sell-side analysts predict that Tenaya Therapeutics, Inc. will post -1.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Tenaya Therapeutics

A number of large investors have recently bought and sold shares of the business. Woodline Partners LP increased its position in Tenaya Therapeutics by 30,563.2% during the first quarter. Woodline Partners LP now owns 5,916,167 shares of the company’s stock worth $3,373,000 after buying an additional 5,896,873 shares during the last quarter. Empery Asset Management LP bought a new stake in shares of Tenaya Therapeutics during the 4th quarter worth about $3,852,000. Vanguard Group Inc. boosted its stake in shares of Tenaya Therapeutics by 6.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,064,857 shares of the company’s stock worth $8,205,000 after acquiring an additional 309,530 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Tenaya Therapeutics by 561.7% during the 3rd quarter. Millennium Management LLC now owns 4,504,592 shares of the company’s stock valued at $7,297,000 after acquiring an additional 3,823,848 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Tenaya Therapeutics by 10.3% in the 4th quarter. Renaissance Technologies LLC now owns 1,850,867 shares of the company’s stock valued at $1,317,000 after acquiring an additional 172,665 shares in the last quarter. 90.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on TNYA shares. HC Wainwright reduced their price target on shares of Tenaya Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, December 12th. Canaccord Genuity Group lowered their price objective on shares of Tenaya Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Chardan Capital cut their target price on shares of Tenaya Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, December 12th. Morgan Stanley set a $2.00 target price on shares of Tenaya Therapeutics in a research note on Thursday, January 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tenaya Therapeutics in a report on Wednesday, January 21st. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $4.50.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.